Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

…, T George, D Zehnder, S Tiberi, NN Aung, A Uriel… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …

[HTML][HTML] GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for≥ 6 months in previously-vaccinated older adults

…, AR Rappaport, DO Koralek, A Uriel… - Nature …, 2023 - nature.com
SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe
complications can occur in older populations. Humoral immunity induced by authorized …

Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study

DS Fierer, AJ Uriel, DC Carriero… - The Journal of …, 2008 - academic.oup.com
Outbreaks of acute hepatitis C virus (HCV) infection are occurring in HIV-infected men who
have sex with men. We evaluated risk factors and liver histopathology in 11 consecutively …

Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men

…, MP Mullen, AD Branch, AJ Uriel… - Clinical infectious …, 2014 - academic.oup.com
Background. There is an international epidemic of hepatitis C virus (HCV) infection among
human immunodeficiency virus (HIV)–infected men who have sex with men. Sustained …

[HTML][HTML] Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

…, A Ustianowski, G Lindergard, A Uriel… - The Lancet …, 2023 - thelancet.com
Background From early in the COVID-19 pandemic, evidence suggested a role for cytokine
dysregulation and complement activation in severe disease. In the TACTIC-R trial, we …

[HTML][HTML] Immunogenicity and safety of AZD2816, a beta (B. 1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously …

…, E Hunter, A Sahdev, D Turner, S Royal, A Uriel… - The Lancet …, 2023 - thelancet.com
Background This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine
expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise …

The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV

TD Schiano, A Uriel, DT Dieterich, MI Fiel - Virchows Archiv, 2011 - Springer
Hepatoportal sclerosis (HPS) is one of several entities known to cause noncirrhotic portal
hypertension. To date, its etiology is unknown. There have been increasing reports of HPS …

Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab

T Wingfield, M Jani, M Krutikov, J Mayer, A Uriel… - …, 2011 - academic.oup.com
SIR, mAb agents, such as infliximab and rituximab, are increasingly prescribed for treatment
of RA. We present a rare case of cryptococcal meningitis in a patient with severe RA after …

Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen

SA Santos, AJ Uriel, JS Park, J Lucas… - European journal of …, 2006 - journals.lww.com
Background In patients with chronic hepatitis B, long-term use of lamivudine is limited by
resistance mutations. Adefovir dipivoxil has a very low rate of resistance, but there have been …

Tumefactive demyelination—an unusual neurological presentation of HIV

A Uriel, R Stow, L Johnson, A Varma… - Clinical infectious …, 2010 - academic.oup.com
We describe 3 individuals infected with human immunodeficiency virus with unusual focal
brain syndromes; magnetic resonance imaging revealed “open-ring” pattern space occupying …